Two Sigma Securities’s Soleno Therapeutics, Inc. Series A Warrant SLNOW Stock Holding History

Two Sigma Securities’s Portfolio SLNOW Stock Details SLNOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,706	Closed	-$2K	–	1368
2017 Q2	$2K	Buy	+2,706	New	+$2.48K	﹤0.01%	827

Other funds holding SLNOW

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Two Sigma Securities's SLNOW Position: Q3 2017 in Review

Two Sigma Securities sold out of Soleno Therapeutics, Inc. Series A Warrant (SLNOW) in Q3 2017, closing a stake of 2,706 shares — an estimated $2K sold.

Two Sigma Securities first reported a position in SLNOW in Q2 2017 and held it in 1 quarter. The position peaked at $2K in Q2 2017. 5 funds tracked by Wall St. Rank hold SLNOW as of Q3 2017.

Two Sigma Securities reported no remaining Soleno Therapeutics, Inc. Series A Warrant position as of Q3 2017 after selling out during the quarter.
Two Sigma Securities sold 2,706 Soleno Therapeutics, Inc. Series A Warrant shares in Q3 2017, an estimated $2K.
Two Sigma Securities first reported a position in Soleno Therapeutics, Inc. Series A Warrant in Q2 2017 and held it in 1 quarter.
Two Sigma Securities's Soleno Therapeutics, Inc. Series A Warrant position peaked at $2K in Q2 2017.
5 funds tracked by Wall St. Rank held Soleno Therapeutics, Inc. Series A Warrant as of Q3 2017.

Based on Two Sigma Securities's 13F filing for Q3 2017, filed 14 Nov 2017.